ArticleOncoimmunology2015
Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 161 citations in OpenAlex.
- Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.BMC cancer · 2018Trial
- Erastin-induced ferroptosis enhances natural killer cell anti-tumor activity and offers therapeutic potential in neuroblastoma.Frontiers in immunology · 2026Article
- The B7-H3/CD3 immune phenotype identifies prognostic subgroups in neuroblastoma.Frontiers in immunology · 2026Article
- Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma.Journal for immunotherapy of cancer · 2025Article
- A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8Scientific reports · 2025Article
- IL-15 functionalized biomimetic hybrid mRNA vaccine for enhanced NSCLC immunotherapy via synergistic activation of T cells and NK cells.Materials today. Bio · 2025Article
- Interplay Between the Epigenome, the Microenvironment, and the Immune System in Neuroblastoma.Cancers · 2025Review
- Targeting Pathways in Neuroblastoma: Advances in Treatment Strategies and Clinical Outcomes.International journal of molecular sciences · 2025Review
- Tertiary Lymphoid Structures Are Associated with Progression-Free Survival of Peripheral Neuroblastic Tumor Patients.Cancers · 2025Article
- Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors.International journal of molecular sciences · 2025Article
- Amyloid precursor-like protein 2 expression in macrophages: differentiation and M1/M2 macrophage dynamics.Frontiers in oncology · 2025Article
- T cells in the microenvironment of solid pediatric tumors: the case of neuroblastoma.Frontiers in immunology · 2025Review
- Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.BMC cancer · 2024Article
- High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy.Journal of clinical medicine · 2024Review
- Oncolytic Viral Therapy in Osteosarcoma.Viruses · 2024Review
- [Role and mechanism of cysteine and glycine-rich protein 2 in the malignant progression of neuroblastoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- The neuroblastoma tumor microenvironment: From an in-depth characterization towards novel therapies.EJC paediatric oncology · 2024Article
- Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature.JCI insight · 2024Article
- PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma.Oncoimmunology · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma grows within an intricate network of different cell types including epithelial, stromal and immune cells. The presence of tumor-infiltrating T cells is considered an important prognostic indicator in many cancers, but the role of these cells in neuroblastoma remains to be elucidated. Herein, we examined the relationship between the type, density and organization of infiltrating T cells and clinical outcome within a large collection of neuroblastoma samples by quantitative analysis of immunohistochemical staining. We found that infiltrating T cells have a prognostic value greater than, and independent of, the criteria currently used to stage neuroblastoma. A variable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.